NSCLC

News

BMS looks to Opdivo + vaccine combo for non-PD-L1 lung cance...

Bristol-Myers Squibb is teaming up with France’s Transgene to combine Opdivo with investigational therapeutic vaccine TG4010 in lung cancer.

News

Roche’s Alecensa beats Xalkori in lung cancer head-to-head

Roche’s new targeted lung cancer treatment Alecensa has shown itself to be superior to Pfizer’s established rival Xalkori in a head-to-head trial as a first line treatment.

News

Natural killer cells are a type of lymphocytes which destroy cancer cells and other altered cells releasing cytotoxic granules.

Novartis' Zykadia gets fast first-line lung cancer review

Roche rival has Breakthrough Therapy status.

News

Roche’s Alecensa approved in Europe, with head-to-head data ...

Alecensa part of Roche's goal of becoming dominant player in NSCLC

News

With all eyes on IO, Tagrisso could be AZ's ace card

AstraZeneca saw revenues decline by 3% and earnings per share fall 5% in 2016 as the expiry of blockbuster Crestor took its toll.

News

Merck soars on Keytruda combination filing

Approval by May could put Keytruda in pole position

BMS looks to Opdivo + vaccine combo for non-PD-L1 lung cance...

Roche’s Alecensa beats Xalkori in lung cancer head-to-head

Novartis' Zykadia gets fast first-line lung cancer review

Roche’s Alecensa approved in Europe, with head-to-head data ...

With all eyes on IO, Tagrisso could be AZ's ace card

Merck soars on Keytruda combination filing

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

NSCLC

Editor's Picks